Paulina Hill PhD

Paulina Hill joined Polaris in 2012 and focuses on investments in healthcare from the Boston office. Paulina serves on the boards of Kala Pharmaceuticals (NASDAQ:KALA), Neuronetics (NASDAQ: STIM), Arsenal Medical, Faraday Pharmaceuticals and KinDex Pharmaceuticals. She is an observer on the boards of 480 Biomedical and Sofregen.
In addition to her investing role, Paulina served as the founding CEO of Polaris-backed CAMP4. She serves on the board of The Capital Network, a non-profit that provides fundraising education to startup entrepreneurs, and is a founding mentor of the Canadian Technology Accelerator.
Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at MIT in Robert Langer’s lab. Paulina is the founding President of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee.
Paulina completed her PhD in Molecular Medicine at Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. ECU honored Paulina with the Incredible Women’s award in 2017.